Navigation Links
New Cimzia® (certolizumab pegol) Data Show a Significant, Rapid Clinical Response and Reduced Disease Activity Among Diverse Patient Populations With Active Rheumatoid Arthritis (RA)
Date:11/9/2010

ATLANTA, Nov. 9, 2010 /PRNewswire/ -- The addition of Cimzia® (certolizumab pegol; CZP) to current therapy was associated with a rapid clinical response, improved function and reduced disease activity in a diverse group of adult rheumatoid arthritis (RA) patients reflecting those seen in daily clinical practice (including those with prior TNF-inhibitor use).  These positive clinical trial data were presented during the American College of Rheumatology's (ACR) 2010 Annual Scientific Meeting in Atlanta, November 7-11. Cimzia®  is approved for the treatment of adults with moderately to severely active rheumatoid arthritis.

"There are patients who live with little relief from the painful symptoms of rheumatoid arthritis due to failed therapies or the severity of the condition," said Roy Fleischmann, MD, clinical professor in the Department of Internal Medicine at the University of Texas Southwestern Medical School.  "These data emphasize that treatment with Cimzia® can substantially provide rapid improvements and help reduce disease activity regardless of the patient's disease history in many of these patients."

The data presented were from the REALISTIC (RA Evaluation in Subjects Receiving TNF Inhibitor Certolizumab Pegol) multicenter phase IIIb study, which included a 12-week, randomized, double-blind (DB), placebo-controlled phase followed by an open-label extension (OLE) (greater than or equal to 16 weeks).  REALISTIC was designed to investigate the safety and efficacy of CZP in a broad patient population with active RA more closely resembling routine clinical practice, versus the pivotal trials, including patients with/without prior TNF-inhibitor exposure, with/without concomitant methotrexate or other disease-modifying anti-rheumatic drugs (DMARDs); and varying lengths of disease duration.

The primary endpoint of an ACR20 score at week 12 was met.  At week 12, more than half (51.1%) of patients in the
'/>"/>

SOURCE UCB
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Rapid and Long-term Clinical Responses Observed in Rheumatoid Arthritis Patients Taking Cimzia® (certolizumab pegol), According to Data Being Highlighted During ACR Meeting
2. UCB Presents Growing Body of Long-term Efficacy Data at ACG 2010 Meeting to Further Support Treatment with Cimzia® (certolizumab pegol) in Multiple Patient Populations with Moderate to Severe Crohns Disease
3. Long-Term Data on Cimzia® (certolizumab pegol) for Moderate to Severe Crohns Disease to be Highlighted at ACG Meeting
4. New Data Show CIMZIA(R) (certolizumab pegol) Provides Sustained and Significant Symptom Improvement in Moderate to Severe Crohns Patients
5. CIMZIA(R) (Certolizumab Pegol) Provides Rapid and Sustained Relief from Signs and Symptoms of Rheumatoid Arthritis for Two Years
6. CIMZIA(R) (Certolizumab Pegol) Provides Long-Term Benefit Without Dose Escalation in Crohns Disease Patients
7. CIMZIA(R) (certolizumab pegol) Reduces Intestinal Lesions and Induces Endoscopic Improvement in Crohns Patients
8. CIMZIA(R) (certolizumab pegol), Significantly Reduces Structural Damage and Rheumatoid Arthritis Signs & Symptoms for Up to One Year
9. Marken Rapidly Responds to Global Supply Chain Security Measures
10. Biosimilar Erosion of Branded ESA Market Share Will be More Rapid in the U.S. Than in Europe
11. Results of Boehringer Ingelheim Oral Hepatitis C Protease Inhibitor and Polymerase Inhibitor Combination Phase Ib Trial Shows Rapid Viral Response Without Use of Pegylated Interferon
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... 1, 2014  CVS Health is thanking its 26,000 ... in changing the way health care is delivered to ... Company,s retail pharmacies, mail service pharmacies and specialty pharmacies ... company name to CVS Health to reflect our broader ... innovations needed to shape the future of health," said ...
(Date:9/30/2014)... , Sept. 30, 2014  Wrightington, ... and Allscripts (NASDAQ: MDRX ) are delighted ... solution as WWL,s new health information system. The system ... will completely transform the way WWL delivers healthcare in ... of a demonstrated record of on-time and on-budget system ...
(Date:9/30/2014)... 30, 2014 STUDY OBJECTIVES The ... to provide an overview of the current and ... drugs/therapeutics. The key objective is to present a ... as an important tool in the treatment of ... future strategies within the protein therapeutics market, which ...
Breaking Medicine Technology:CVS Health Thanking its Pharmacists during American Pharmacists Month for Helping People on Their Path to Better Health 2CVS Health Thanking its Pharmacists during American Pharmacists Month for Helping People on Their Path to Better Health 3Wrightington, Wigan and Leigh NHS Foundation Trust selects Allscripts Sunrise 2Wrightington, Wigan and Leigh NHS Foundation Trust selects Allscripts Sunrise 3Wrightington, Wigan and Leigh NHS Foundation Trust selects Allscripts Sunrise 4Global Markets and Manufacturing Technologies for Protein Drugs -- Focus on Cytokines and Monoclonal Antibodies 2Global Markets and Manufacturing Technologies for Protein Drugs -- Focus on Cytokines and Monoclonal Antibodies 3Global Markets and Manufacturing Technologies for Protein Drugs -- Focus on Cytokines and Monoclonal Antibodies 4
... Mo., Sept. 10 K-V Pharmaceutical Company (NYSE:  KVa/KVb) ... U.S. Food and Drug Administration ("FDA") of the successful ... approval to return its first product to market.  Under ... Company,s quality systems, processes and facilities are expected to ...
... CITY, Calif., Sept. 9 Avinger, Inc., a ... innovative devices to combat peripheral artery disease, announces ... CONNECT (Chronic TOtal OcclusioN CrossiNg with thE WildCat ... prospective, multi-center, non-randomized study intended to evaluate the ...
Cached Medicine Technology:K-V Pharmaceutical Company Announces Completion of U.S. Food and Drug Administration Inspection and Approval to Return its First Product to Market 2K-V Pharmaceutical Company Announces Completion of U.S. Food and Drug Administration Inspection and Approval to Return its First Product to Market 3K-V Pharmaceutical Company Announces Completion of U.S. Food and Drug Administration Inspection and Approval to Return its First Product to Market 4K-V Pharmaceutical Company Announces Completion of U.S. Food and Drug Administration Inspection and Approval to Return its First Product to Market 5K-V Pharmaceutical Company Announces Completion of U.S. Food and Drug Administration Inspection and Approval to Return its First Product to Market 6K-V Pharmaceutical Company Announces Completion of U.S. Food and Drug Administration Inspection and Approval to Return its First Product to Market 7K-V Pharmaceutical Company Announces Completion of U.S. Food and Drug Administration Inspection and Approval to Return its First Product to Market 8First Patient Enrolled in 'CONNECT' Clinical Trial 2
(Date:10/1/2014)... more than 80 per cent of bowel cancers could ... that medicines called ,JAK inhibitors, halted tumour growth in ... in more than 80 per cent of bowel cancers. ... clinical trials, for diseases including rheumatoid arthritis, psoriasis, blood ... second-most common cancer in Australia with nearly 17,000 people ...
(Date:10/1/2014)... New research co-funded by the Engineering and Physical ... cyber-security of the UK,s vital industrial control systems ... the electricity grid, and the rail network. ... threats from hackers or malware infiltrating the systems ... Research Institute in Trustworthy Industrial Control Systems (RITICS), ...
(Date:10/1/2014)... to keep their "eyes on the prize" may be ... staying focused on a specific target ahead can make ... walk there faster, psychology researchers have found. Their study, ... the environment naturally, offers a new strategy to improve ... in exercise if physical activity seems daunting, which can ...
(Date:10/1/2014)... Insuranceragents.info has released a new blog post explaining how ... family members. , Life insurance plans provide important financial ... should always carry a life insurance policy as their ... the family. , Clients can choose from several ... coverage or from a permanent policy. No medical exam ...
(Date:10/1/2014)... First Warning Systems, a pioneer in early ... the body, announced the company is changing its name ... breadth of upcoming product releases. The initial focus will ... “Our initial focus will be an ‘Internet of Everthing,’ ... cellular changes over time,” said Rob Royea, president and ...
Breaking Medicine News(10 mins):Health News:Eighty percent of bowel cancers halted with existing medicines 2Health News:£2.5 million to recognize and reduce cyber-attack threats to critical infrastructure 2Health News:Keeping your eyes on the prize can help with exercise, NYU study finds 2Health News:Keeping your eyes on the prize can help with exercise, NYU study finds 3Health News:Life Insurance for Families - Clients Can Compare Affordable Rates Online! 2Health News:First Warning Systems Changes Name to Cyrcadia Health to Better Reflect Core Competency and Goals of Company 2Health News:First Warning Systems Changes Name to Cyrcadia Health to Better Reflect Core Competency and Goals of Company 3Health News:First Warning Systems Changes Name to Cyrcadia Health to Better Reflect Core Competency and Goals of Company 4
... drugs to fix what healthy living would cure, researcher says, ... eating right, exercising and keeping your weight down are well-known, ... , In fact, over the past two decades exercise rates ... in the meantime obesity rates have soared, a new study ...
... TORONTO, Ont., May 28, 2009 When Chicago Blackhawk,s ... game four of the Western Conference Final after sustaining ... surrounding his swift return. According to a new study ... questions were raised by 25% of minor league hockey ...
... leaders for vision, determination and drive to address today,s ... , a part of Experian and a leader ... that its president, Daniel Johnson, has been named as ... the Year(R) Award in Minnesota and the Dakotas."I am ...
... the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) will establish ... been made by the responsible Grants Committee of the ... centres will initially be funded for four years with ... this, the DFG will also provide 20 percent overhead ...
... launches campaign for stricter regulatory approval requirements and continuity of product ... ... 2009 -- A recent report released by Wolters Kluwer Health predicts ... drug prescriptions will be filled with generic drugs. This march ...
... HEIGHTS, Ohio, May 27 Allscripts announced today ... Allscripts Professional(R) Electronic Health Record ... multi-specialty practices across suburban Cleveland, Ohio. (Logo: ... hospital and health center with its own physician ...
Cached Medicine News:Health News:Americans Score Low on Healthy Lifestyle 2Health News:Americans Score Low on Healthy Lifestyle 3Health News:Minor league hockey players unable to identify concussion symptoms, study says 2Health News:Minor league hockey players unable to identify concussion symptoms, study says 3Health News:SearchAmerica(R) President Named as a Finalist for the Ernst & Young Entrepreneur of the Year(R) Award 2Health News:SearchAmerica(R) President Named as a Finalist for the Ernst & Young Entrepreneur of the Year(R) Award 3Health News:DFG establishes nine new collaborative research centers 2Health News:DFG establishes nine new collaborative research centers 3Health News:DFG establishes nine new collaborative research centers 4Health News:DFG establishes nine new collaborative research centers 5Health News:DFG establishes nine new collaborative research centers 6Health News:In the Case of Epilepsy, Generic Drugs and Random Product Substitution are Not Always "Good Medicine" 2Health News:In the Case of Epilepsy, Generic Drugs and Random Product Substitution are Not Always "Good Medicine" 3Health News:In the Case of Epilepsy, Generic Drugs and Random Product Substitution are Not Always "Good Medicine" 4Health News:In the Case of Epilepsy, Generic Drugs and Random Product Substitution are Not Always "Good Medicine" 5Health News:Southwest General Health Center Selects Allscripts Web-Hosted Electronic Health Record 2Health News:Southwest General Health Center Selects Allscripts Web-Hosted Electronic Health Record 3Health News:Southwest General Health Center Selects Allscripts Web-Hosted Electronic Health Record 4Health News:Southwest General Health Center Selects Allscripts Web-Hosted Electronic Health Record 5
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: